Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of MVC-COV1901 Vaccine
NCT04487210Phase 1Completed
- Sponsor
- Medigen Biotechnology
- Start
- Oct 2020
- Primary completion
- Jun 2021
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of MVC-COV1901 in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Medigen Biotechnology. Primary endpoint: Safety of MVC-COV1901. Started Oct 2020; status: completed.
02
Drugs
MVC-COV1901
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04487210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04487210.